RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal Canal

Lisa A. Kachnic(Boston Medical Center), Kathryn Winter(RTOG Foundation), Robert J. Myerson(Washington University in St. Louis), Michael Goodyear(Dalhousie University), John Willins(Boston Medical Center), Jacqueline Esthappan(Washington University in St. Louis), Michael G. Haddock(Mayo Clinic), Marvin Rotman(SUNY Downstate Health Sciences University), Parag J. Parikh(Washington University in St. Louis), Howard Safran(Brown University), Christopher G. Willett(Duke University)
International Journal of Radiation Oncology*Biology*Physics
November 12, 2012
10.1016/j.ijrobp.2012.09.023
Cited by 622Open Access
Full Text

Abstract

Related Papers

Optimal two-stage designs for phase II clinical trials
Richard Simon|Controlled Clinical Trials|1989|3.6k
Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.
Harry Bartelink, F. Roelofsen, F. Eschwège et al.|Journal of Clinical Oncology|1997|1.3k
Combined therapy for cancer of the anal canal
Norman D. Nigro, V. K. Vaitkevicius, Basil Considine|Diseases of the Colon & Rectum|1974|1.1k
Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.
Marshall S. Flam, Michelle E. St. John, Thomas F. Pajak et al.|Journal of Clinical Oncology|1996|1.1k
Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin
|The Lancet|1996|1k